Mast Therapeutics, Inc. (MSTX)

[leoncio1]

ADVENTRX Announces 12-Month Stability Data Results for ANX-530

SAN DIEGO, Sept. 14 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured at the Company's intended commercial manufacturing site. The 12-month stability data are consistent with the stability data collected at 6 and 9 months and will support the Company's submission of a New Drug Application (NDA) for Exelbine, which the Company expects to take place in the fourth quarter of this year.